# Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy

- Link: https://www.thailand-business-news.com/pr-news/gene-solutions-advances-precision-oncology-education-in-malaysia-with-the-beyond-actionable-academy
- Published: 2026-08-04T05:00:00+07:00
- Author: PR Newswire

_At the Precision Oncology Academy 2026, leading international experts explored 
how insights from tumour DNA and RNA can reveal treatment opportunities, explain
drug resistance, and translate into more confident treatment decisions to improve
cancer care._

KUALA LUMPUR, Malaysia, Aug. 4, 2026 /PRNewswire/ — [Gene Solutions](https://genesolutions.com/)
Malaysia hosted the Precision Oncology Academy 2026 on 25 July 2026 at the Sheraton
Petaling Jaya Hotel under the theme ”Beyond Actionable”. An extension of the international
[**K-CONNECT Platform**](https://kconnect.genesolutions.com/) and the recent [**K-CONNECT Summit 2026 in Vietnam**](https://genesolutions.com/news/best-of-k%e2%80%91connect-summit-2026-translating-multi-omics-and-ai-into-real-world-precision-oncology),
the Academy brought together oncology experts from the United Arab Emirates, Singapore,
Malaysia, US and Vietnam. Through scientific lectures, multidisciplinary case discussions
and interactive workshops, the programme addressed a central question: How can a
deeper understanding of each patient’s cancer lead to more informed treatment decisions?

 [⌊Gene Solutions Advances Precision Oncology Education in Malaysia with the ‘’Beyond Actionable’’ Academy⌉](https://mmx.prnasia.com/media/MS1962760/20260803035214EDT_image_1.jpg?id=OA2821325&p=medium600)

Gene Solutions Advances Precision Oncology Education in Malaysia with the ‘’Beyond
Actionable’’ Academy

The Academy’s expert faculty was led by Chairperson **Prof. Dr. Ho Gwo Fuang** of
Curie Oncology, Malaysia, and Co-chairperson **Prof. Dr. Darren Lim Wan-Teck** of
the National Cancer Centre Singapore. They were joined by **Prof. Dr. Shaheenah 
Dawood** of Mediclinic Middle East, UAE; **Dr. Christina Lai Nye Bing** of Hospital
Picaso, Malaysia; **Dr. Katherine Teh Hooi Lay** of Gleneagles Hospital Johor, Malaysia;**
Dr. Jenson Sow Wen Jen** of Curie Oncology, Malaysia; **Dr. Sinh Nguyen Duy** and**
Dr.** **Lan Tu Ngoc Ly** of Gene Solutions. Together, the faculty brought expertise
spanning clinical oncology, cancer genomics, molecular diagnostics and genomic data
interpretation, creating a multidisciplinary forum for translating complex molecular
insights into practical clinical decisions.

**Decoding the molecular story of cancer**

Cancer is not defined solely by its site of origin in the body. Every tumour carries
a complex molecular story, written in changes across its DNA and RNA. These changes
influence how cancer develops, how it responds to treatment and how it may become
resistant over time.

The Academy examined how large genomic and transcriptomic panels comprehensive profiling
can provide a broader view of tumour biology. This includes comprehensive multi-
omic approaches such as [**K-4CARE**](https://genesolutions.com/our-test/k-4care),
which combines tissue-based DNA and RNA profiling with liquid biopsy circulating
tumour DNA (ctDNA) analysis for both molecular profiling and ongoing monitoring.
DNA profiling may identify genomic alterations associated with cancer growth and
reveal biomarkers linked to targeted therapies, immunotherapies or clinical trials.
RNA analysis can detect clinically important gene fusions and splice variants that
may be missed or remain unclear through DNA-only testing.

The discussions highlighted the complementary roles of tissue and liquid (plasma)
next-generation sequencing. While tissue testing remains essential for initial diagnosis
and detailed characterisation, liquid biopsy can capture a wider view of tumour 
heterogeneity and resistance, particularly at progression. Used together, the two
approaches offer clinicians a more complete molecular picture to guide treatment
decisions.

The value of tissue and liquid longitudinal molecular profiling was illustrated 
by Prof. Dr. Darren Lim, who presented a real-world case of a patient with ALK-positive
lung cancer managed over several years with serial next-generation sequencing. The
case illustrated how repeated molecular profiling — combining tissue and plasma 
testing — can reveal a broader resistance landscape and support sequential treatment
decisions throughout a patient’s journey.

Together, DNA, RNA, and ctDNA insights can provide clinicians with a more comprehensive
understanding of the tumour. Molecular testing does not guarantee an actionable 
finding or suitable treatment, but it may uncover important information that would
otherwise remain unseen.

**Following cancer as it evolves**

The Academy also highlighted the growing role of liquid biopsy in providing a more
dynamic and holistic view of cancer.

One of the Academy’s key international speakers, **Prof**. **Dr. Shaheenah Dawood**,
shared clinical perspectives on the evolving role of minimal residual disease (MRD)
and ctDNA monitoring across cancer types. Prof. Dr. Dawood also reviewed the latest
ASCO and NCCN guideline updates on liquid biopsy.

While tissue biopsy examines tumour material obtained from a particular location
at a particular point in time, liquid biopsy detects cancer-related signals, including
ctDNA, in the blood and can be repeated with a single blood draw. Depending on the
clinical context and available evidence, liquid biopsy may help clinicians monitor
treatment response, investigate emerging resistance or detect molecular signs of
MRD. Because it can be performed repeatedly over time, liquid biopsy also offers
the potential to follow how a cancer changes throughout treatment.

"The future of cancer management is dynamic. Liquid biopsy enables continuous monitoring
of tumour evolution, helping clinicians make earlier, more informed treatment decisions."
said** Prof. Shaheenah Dawood.**

**From complex data to confident decisions**

The speakers emphasized that precision oncology is not simply about testing more
genes or generating more data. The real challenge is determining which findings 
are clinically meaningful for an individual patient.

Not every molecular alteration drives cancer, and not every detected alteration 
can guide treatment. When a potentially actionable biomarker is identified, clinicians
must consider the strength of the supporting evidence, the cancer type, previous
treatments, the patient’s overall condition, and the availability of appropriate
therapies or clinical trials.

This is why genomic findings must be interpreted together with pathology, medical
history, and multidisciplinary clinical expertise.

"Precision oncology is no longer just about generating genomic data. It is about
translating genomic insights, including MRD and ctDNA, into confident clinical decisions
that improve patient care." said** Prof. Ho Gwo Fuang** who chaired the Academy.

**Connecting regional knowledge with clinical practice**

The Precision Oncology Academy followed the **K-CONNECT Summit 2026 | AI & Multi-
omics – Shifting Paradigms in the New Era of Early Cancer Detection and Precision
Oncology**, recently held in Vietnam.

K-CONNECT was established by Gene Solutions as an international platform for multidisciplinary
exchange in cancer genomics, ctDNA, molecular residual disease monitoring, comprehensive
genomic and transcriptomic profiling, artificial intelligence and precision medicine.

"The K-CONNECT Platform was created to foster collaboration across the region, while
Precision Oncology Academy translates that collaboration into practical clinical
learning. By bringing together leading experts and real-world evidence, we hope 
to empower clinicians to confidently integrate precision oncology into routine patient
care." said **Lim Chiun Khee, Country Director, Gene Solutions Malaysia.**

For patients and families, cancer genomics may appear complex, but its purpose is
clear: to understand the disease more completely so that treatment decisions can
become more precise.

Through the K-CONNECT Platform, K-CONNECT Summit and Precision Oncology Academy,
Gene Solutions continues to connect scientific advancement with clinical practice,
helping make the evolving possibilities of precision oncology more accessible to
clinicians and, ultimately, more meaningful for patients.

**About Gene Solutions **

**Gene Solutions** is a global biotechnology company headquartered in Singapore 
with a mission to make advanced genomic solutions accessible and affordable. Leveraging
next-generation sequencing, multi-omics and artificial intelligence, the company
offers a portfolio of solutions across multi-cancer detection, precision oncology
and reproductive health, including [**SPOT-MAS**](https://spotmas.com/), [**K-TRACK**](https://genesolutions.com/our-test/k-track)
and [**K-4CARE**](https://genesolutions.com/our-test/k-4care).

Gene Solutions operates CAP-accredited NGS laboratories and has delivered millions
of genetic tests worldwide since 2017. For more information, visit [**www.genesolutions.com**](https://www.genesolutions.com/)
and follow Gene Solutions on [**LinkedIn**](https://www.linkedin.com/company/genesolutions)**,**
[**Facebook**](https://www.facebook.com/GeneSolutions.Global/)**, **and [**X (Twitter)**](https://x.com/GS_bio).

For inquiries, please contact **[pr@genesolutions.com](https://www.thailand-business-news.com/pr-news/pr@genesolutions.com)**

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Gene Solutions Advances Precision Oncology Education in Malaysia with the ''Beyond Actionable'' Academy ](http://www.prnasia.com/story/archive/5017472_AE17472_0?rand=184833)
